- Home
- DIT vs SGMT Comparison
DIT vs SGMT Comparison
Compare DIT & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIT
- SGMT
- Stock Information
- Founded
- DIT 1981
- SGMT 2006
- Country
- DIT United States
- SGMT United States
- Employees
- DIT N/A
- SGMT 14
- Industry
- DIT Food Distributors
- SGMT
- Sector
- DIT Consumer Discretionary
- SGMT
- Exchange
- DIT Nasdaq
- SGMT Nasdaq
- Market Cap
- DIT 78.7M
- SGMT 71.2M
- IPO Year
- DIT 1995
- SGMT 2023
- Fundamental
- Price
- DIT $106.60
- SGMT $3.15
- Analyst Decision
- DIT
- SGMT Strong Buy
- Analyst Count
- DIT 0
- SGMT 6
- Target Price
- DIT N/A
- SGMT $25.67
- AVG Volume (30 Days)
- DIT 218.0
- SGMT 722.3K
- Earning Date
- DIT 04-18-2025
- SGMT 05-14-2025
- Dividend Yield
- DIT 0.92%
- SGMT N/A
- EPS Growth
- DIT N/A
- SGMT N/A
- EPS
- DIT 2.44
- SGMT N/A
- Revenue
- DIT $2,221,421,072.00
- SGMT N/A
- Revenue This Year
- DIT N/A
- SGMT N/A
- Revenue Next Year
- DIT N/A
- SGMT N/A
- P/E Ratio
- DIT $47.91
- SGMT N/A
- Revenue Growth
- DIT 7.47
- SGMT N/A
- 52 Week Low
- DIT $99.87
- SGMT $1.73
- 52 Week High
- DIT $174.99
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- DIT 34.75
- SGMT 57.17
- Support Level
- DIT $99.87
- SGMT $1.84
- Resistance Level
- DIT $123.98
- SGMT $3.25
- Average True Range (ATR)
- DIT 4.23
- SGMT 0.27
- MACD
- DIT -0.54
- SGMT 0.15
- Stochastic Oscillator
- DIT 27.86
- SGMT 93.42
About DIT AMCON Distributing Company
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores, and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.